Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice

IF 2.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia Pub Date : 2024-08-10 DOI:10.1016/j.abd.2024.04.004

Miguel Mansilla-Polo , Antonio Sahuquillo-Torralba , Conrad Pujol-Marco , Guillermo Bargues-Navarro , Rafael Botella-Estrada

引用次数: 0

查看原文本刊更多论文

Guselkumab、Risankizumab和Tildrakizumab在银屑病治疗中显示出平行的有效性和安全性：一项在真实临床实践中进行的头对头比较研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anais brasileiros de dermatologia DERMATOLOGY-

CiteScore

2.40

自引率

0.00%

发文量

184

审稿时长

32 days

期刊介绍： The journal is published bimonthly and is devoted to the dissemination of original, unpublished technical-scientific study, resulting from research or reviews of dermatological topics and related matters. Exchanges with other publications may be accepted.